How do you incorporate oncotype Dx recurrence score when planning adjuvant CDK 4/6 inhibitor for high risk early stage HR+ breast cancer?   

Since Oncotype Dx recurrence score was not used for eligibility to monarchE trial, I do not use it to select patients for adjuvant abemaciclib. I personally stick to criteria used on monarchE, i.e. 4 or more involved axillary lymph nodes, or one to three positive nodes and either grade 3 disease or ...